Contraceptive Technology Update – April 1, 2012
April 1, 2012
View Issues
-
The 'Get It and Forget It' methods are here: Remove obstacles to use
Where do long-acting reversible contraceptives (LARC) fit in at your facility? How are you encouraging women to use the "Get It and Forget It" methods? If you are seeing low numbers of women choosing intrauterine devices (IUDs) or the contraceptive implant, you might want to change your counseling strategy. -
Circumcision devices eyed in HIV prevention
Now that male circumcision has been associated with a lower risk for HIV infection in international observational studies and in three randomized controlled clinical trials, international health officials are looking at options in making it more available to men at risk. -
Pfizer issues recalls for Akrimax OCs
Has your clinic telephone been ringing recently with calls from women who have heard about a birth control pill recall? Chances are, few, if any, of your patients were using the affected oral contraceptives (OCs). -
Ulipristal acetate: New fibroid treatment?
Ulipristal acetate, the drug recently approved as an emergency contraceptive in the United States (Ella, Watson Pharmaceuticals, Morristown, NJ), is being eyed for other gynecologic uses. In research looking at women with symptomatic fibroids who were planning to undergo surgery, treatment with the selective progesterone-receptor modulator was effective in controlling excessive bleeding and reducing fibroid size at 13 weeks. -
HPV shot doesn't trigger autoimmune response
New research indicates that the human papillomavirus vaccine (HPV) Gardasil (Merck & Co.) does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, type 1 diabetes, or multiple sclerosis after vaccination in young women. -
Study confirms impact of OCs on dysmenorrhea
Results from a large, long-running Scandinavian study provides convincing evidence that combined oral contraceptives (OCs) alleviate the symptoms of dysmenorrhea, painful menstrual periods.